No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis

BackgroundFingolimod (FTY) is a sphingosine 1 phosphate (S1P) agonist with significant effects on immune cell distribution used as an effective disease modifying therapy in multiple sclerosis (MS) patients. Animal studies have demonstrated that a dysregulation of egress of murine secretory Immunglob...

Full description

Bibliographic Details
Main Authors: Hernan Inojosa, Judith Eisele, Undine Proschmann, Sebastian Zeissig, Katja Akgün, Tjalf Ziemssen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
multiple sclerosis
fingolimod
secretory immunglobulin A
sIgA
microbiome
gut immune system
Online Access:https://www.frontiersin.org/article/10.3389/fcell.2020.567659/full

Internet

https://www.frontiersin.org/article/10.3389/fcell.2020.567659/full

Similar Items